You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The US DOJ alleged that the company conspired to "artificially delay" ordering its MammaPrint test in order to circumvent Medicare's 14-day rule.
In January a federal court unsealed a False Claims Act suit from an industry insider that alleges a Myriad subsidiary engaged in a fraudulent kickback scheme.
Illumina had sought to exclude the Harmony test from the US Market, while Ariosa had sought to overturn the jury verdict with a post-trial maneuver.
The plaintiffs allege that TAI's heart transplant rejection test MyTAIHeart infringes on their patent for the non-invasive diagnosis of graft rejection.
Under a settlement, Yikon agreed to immediately stop advertising, marketing, and selling its serology test kits and to refund customers who purchased them.
Of the 28 companies in the 360 Index, six companies' share prices increased while the share values of 22 declined month over month.
The lawsuit also alleges Anthem failed to delete inaccurate diagnosis codes, leading to inflated risk-adjustment payments from Medicare.
Labrador Diagnostics, a firm controlled by an investment group that acquired Theranos' IP, alleged BioFire's FilmArray products infringe two patents.
The US Court of Appeals for the Federal Circuit sent the case, which had been thrown out in December 2018, back to the trial court.
The company's original lawsuit, filed last March, accused Natera of infringing on two patents it holds in conjunction with Stanford University.